This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Hold on to Edwards Lifesciences for Now
by Zacks Equity Research
Investors continue to be upbeat about Edwards Lifesciences (EW) owing to its strong segmental growth and robust product demand.
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Quest Diagnostics (DGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DGX) Outperforming Other Medical Stocks This Year?
IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests
by Zacks Equity Research
IDEXX's (IDXX) human health business, OPTI Medical Systems' newly-developed PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR gains market acceptance.
Boston Scientific's (BSX) ICM System Receives FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.
Here's Why You Should Retain DaVita in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA), thanks to solid prospects.
Myriad Genetics Unveils New Home DNA Sample Collection Kit
by Zacks Equity Research
Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.
QIAGEN's (QGEN) Selloff Deal With Thermo Fisher Progresses
by Zacks Equity Research
QIAGEN's (QGEN) acquisition deal with Thermo Fisher receives approval from QIAGEN shareholders.
NextGen Virtual Visits Offers Remote Eye Care Facilities
by Zacks Equity Research
The offering will expand NextGen's (NXGN) ophthalmology services during the coronavirus crisis.
Masimo's New Solution to Reduce Opioid Withdrawal Symptoms
by Zacks Equity Research
Masimo's (MASI) new solution can help reduce symptoms associated with opioid withdrawal, thereby helping OUD patients with their treatment.
Abbott, Tandem Diabetes Seal Deal on Diabetes Management
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.
LabCorp's Xcellerate Coronavirus Solution to Aid Clinical R&D
by Zacks Equity Research
This solution by LabCorp (LH) takes the idea from Covance's COVID-19 Operational Recovery Team to better understand the necessities.
Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe
by Zacks Equity Research
The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Allscripts (MDRX) continues to benefit from lucrative deals and strong prospects in Sunrise EHR. However, margin contraction remains a woe.
Luminex Expands COVID-19 Testing With New Antibody Test
by Zacks Equity Research
Luminex (LMNX) submits an EUA request to the FDA for its first multi-antigen IgG assay.
LHC Group Inks Deal With Orlando Health to Improve HCBS
by Zacks Equity Research
This deal is expected to boost LHC Group's (LHCG) home and community-based business segment.
Myriad Genetics' myPath Melanoma Proved Superior Per New Study
by Zacks Equity Research
Myriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study.
Here's Why You Should Hold on to Illumina Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
Masimo's (MASI) New Offering to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) Centroid gets FDA clearance and can help clinicians monitor patient position, thereby improving patient outcomes.
Ecolab's Unit Unveils Test Kit for Cooling Water Management
by Zacks Equity Research
Ecolab's (ECL) bacteria test kit drastically simplifies water-chemistry testing and compliance for cooling water health.
LabCorp Neutralizing Antibody Test to Aid Coronavirus Vaccine R&D
by Zacks Equity Research
The information related to neutralizing antibody test of LabCorp (LH) can also be used for the screening of convalescent plasma for prophylactic and therapeutic use.
Medtronic's DBS System With BrainSense Technology Gets FDA Nod
by Zacks Equity Research
Medtronic's (MDT) first-of-its-kind Percept PC DBS system with the next-generation BrainSense technology clears FDA hurdle, paving the way for data-driven neurostimulation treatment.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be upbeat about ResMed (RMD) owing to its strong emphasis on product development and consistent high demand for its critical care products.
Ooma, Chico's, Ericsson, Quest and Kroger as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ooma, Chico???s, Ericsson, Quest and Kroger as Zacks Bull and Bear of the Day